AbbVie (NYSE:ABBV) Hits New 12-Month High on Analyst Upgrade

Shares of AbbVie Inc. (NYSE:ABBV) hit a new 52-week high during mid-day trading on Wednesday after Scotiabank raised their price target on the stock from $280.00 to $320.00. Scotiabank currently has an outperform rating on the stock. AbbVie traded as high as $271.96 and last traded at $271.45, with a volume of 251867 shares. The stock had previously closed at $266.69.

Several other equities analysts have also weighed in on the company. Piper Sandler increased their price objective on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. HSBC increased their price target on AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Royal Bank Of Canada boosted their price objective on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research note on Friday, July 10th. Canaccord Genuity Group increased their target price on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Finally, BNP Paribas Exane boosted their price target on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $273.82.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.06% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The FDA granted two Breakthrough Therapy Designations for AbbVie’s investigational telisotuzumab adizutecan (Temab-A) in colorectal cancer and non-small cell lung cancer. The designations strengthen AbbVie’s antibody-drug conjugate portfolio and could accelerate regulatory discussions if clinical results remain positive. AbbVie Temab-A Breakthrough Therapy Designations
• Positive Sentiment: AbbVie and Genmab reported that epcoritamab plus R-CHOP reduced the risk of progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The Phase 3 win supports potential expansion of Epkinly into frontline treatment and positions the combination as a possible competitor to Roche’s Polivy, with regulatory discussions planned. Epcoritamab Phase 3 DLBCL Results
• Positive Sentiment: Scotiabank raised its AbbVie price target from $280 to $320 and maintained a “sector outperform” rating, implying further potential upside. The broader analyst consensus remains equivalent to a Buy, although ratings are not guarantees of performance. Scotiabank Raises AbbVie Price Target
• Neutral Sentiment: AbbVie is scheduled to report third-quarter results later this month. Investors will focus on Humira replacement growth, newer immunology and oncology products, and whether full-year guidance is maintained.
• Negative Sentiment: AbbVie lowered third-quarter 2026 adjusted EPS guidance to $3.73–$3.77 from the prior outlook of $3.85, citing $216 million of acquired in-process research and development and milestone expenses. Full-year adjusted EPS guidance was also reduced to $13.76–$13.96.
• Negative Sentiment: One analysis highlighted a payout ratio above 190%, raising questions about the sustainability of AbbVie’s dividend if earnings do not improve or special expenses continue. The stock’s elevated valuation also leaves less room for disappointment.

Institutional Trading of AbbVie

A number of hedge funds have recently made changes to their positions in ABBV. Ranch Capital Advisors Inc. lifted its holdings in shares of AbbVie by 37.0% during the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after acquiring an additional 4,017 shares during the period. Capital Advisors Inc. OK increased its position in AbbVie by 11.2% during the second quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock worth $112,516,000 after purchasing an additional 45,132 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab acquired a new position in AbbVie during the second quarter worth approximately $23,557,000. Wedge Capital Management L L P NC raised its stake in AbbVie by 7.5% during the second quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock worth $33,865,000 after purchasing an additional 9,380 shares during the period. Finally, Mission Wealth Management LP boosted its holdings in shares of AbbVie by 119.1% in the 2nd quarter. Mission Wealth Management LP now owns 69,052 shares of the company’s stock valued at $17,376,000 after purchasing an additional 37,531 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Performance

The company has a market cap of $481.62 billion, a price-to-earnings ratio of 76.89, a price-to-earnings-growth ratio of 1.20 and a beta of 0.24. The stock’s fifty day simple moving average is $258.12 and its two-hundred day simple moving average is $235.42.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts predict that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.5%. AbbVie’s payout ratio is 195.48%.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.